Equites Radar

GMED · Globus Medical, Inc.

Medical DevicesUnited StatesAnalyst view: Buy

$75.42

+3.71% last session

End-of-day data · updated 2026-07-25

Bearish0 bullish · 4 bearish technical signals
Consensus: Buy (1.79 from 12 analysts)
To mean target: +40.2%

Market cap

$10B

Enterprise value

$10B

Trailing P/E

17.9

Forward P/E

14.9

Dividend yield

Beta

0.95

Avg volume

2M

Employees

6K

2D change

1.42%

5D change

0.63%

10D change

-2.63%

30D change

-9.64%

60D change

-10.12%

MTD change

0.70%

YTD change

-12.39%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.79
Covering analysts12
Mean price target$105.75
Low price target$87.00
Upside to mean target+40.2%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)49.3
50-day MA$79.53
200-day MA$83.42
Price vs 50-day MA-1.7%
Price vs 200-day MA-6.2%
MACD histogram-0.06
Volume vs 3-month avg0.1×
52w low $52.6352w high $96.82

Analyst sentiment over time — GMED

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-28

Latest call per bank · past 12 months

UBS

Neutral

$82.00

+8.7% vs price
▲ raised from $0.00Initiates · 2026-07-28

RBC Capital

Outperform

$115

+52.5% vs price
▼ cut from $120Maintains · 2026-07-13

Wells Fargo

Overweight

$103

+36.6% vs price
▼ cut from $104Maintains · 2026-05-08

Barclays

Overweight

$123

+63.1% vs price
▲ raised from $118Maintains · 2026-02-25

Morgan Stanley

Overweight

$100

+32.6% vs price
▲ raised from $70.00Maintains · 2025-12-02

Bank of America

Buy

$91.00

+20.7% vs price
▲ raised from $65.00Upgrade · 2025-11-07

Recent rating actions

DateFirmActionRatingPrice target
2026-07-28UBSInitiatesNeutral$0.00 $82.00
2026-07-16Truist SecuritiesMaintainsBuy$115 $100
2026-07-13RBC CapitalMaintainsOutperform$120 $115
2026-07-09BMO CapitalInitiatesOutperform$0.00 $94.00
2026-07-08StifelMaintainsHold$95.00 $80.00
2026-06-15Piper SandlerMaintainsOverweight$115 $100
2026-05-08RBC CapitalMaintainsOutperform$115 $120
2026-05-08Wells FargoMaintainsOverweight$104 $103

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-27

  • RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 1.6% below the 50-day MA ($79.53).
  • Price vs 200-day MA: Trading 6.2% below the 200-day MA ($83.42).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.06) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($52.63) and high ($96.82).

GMED Price Chart

Loading chart for GMED

Fundamentals

Revenue (TTM)$3.0B
EBITDA$1.0B
Free cash flow$0M
Operating cash flow$1.0B
Book value / share$34.88
Net debt / EBITDA-0.5
WACC11.0%
Revenue growth27.00%
Earnings growth67.00%

About Globus Medical, Inc.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

More in Medical Devices

Screen GMED against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.